144 related articles for article (PubMed ID: 31579984)
61. Relative potency of bicalutamide (Casodex) and flutamide (Eulexin).
Kolvenbag GJ; Furr BJ
Urology; 1999 Jul; 54(1):194-7. PubMed ID: 10414753
[No Abstract] [Full Text] [Related]
62. Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: A retrospective review of 35 patients.
Moussa A; Kazmi A; Bokhari L; Sinclair RD
J Am Acad Dermatol; 2022 Aug; 87(2):488-490. PubMed ID: 34740752
[No Abstract] [Full Text] [Related]
63. [The role of bicalutamide in the treatment of prostate cancer].
Stav SY; Segal G
Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896
[TBL] [Abstract][Full Text] [Related]
64. Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy.
Di Silverio F; Sciarra A; Gentile V
Urology; 2008 May; 71(5):947-51. PubMed ID: 18279940
[TBL] [Abstract][Full Text] [Related]
65. Bicalutamide ('Casodex') development: from theory to therapy.
Kolvenbag GJ; Furr BJ
Cancer J Sci Am; 1997; 3(4):192-203. PubMed ID: 9263623
[No Abstract] [Full Text] [Related]
66. Mixed acinar and macrocystic ductal prostatic adenocarcinoma.
Giganti F; Allen C; Sridhar A; Tandogdu Z; Ramachandran N; Dickinson L; Haider A; Freeman A; Ball R; Moore CM
Lancet Oncol; 2021 Jan; 22(1):e37. PubMed ID: 33387504
[No Abstract] [Full Text] [Related]
67. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.
Joyce R; Fenton MA; Rode P; Constantine M; Gaynes L; Kolvenbag G; DeWolf W; Balk S; Taplin ME; Bubley GJ
J Urol; 1998 Jan; 159(1):149-53. PubMed ID: 9400459
[TBL] [Abstract][Full Text] [Related]
68. A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy.
Bryk DJ; Angermeier KW; Klein EA
Urology; 2019 Jul; 129():e4-e5. PubMed ID: 30935936
[TBL] [Abstract][Full Text] [Related]
69. Reply to: "Comment on: Bicalutamide Improves Minoxidil-Induced Hypertrichosis in Female Pattern Hair Loss: A Retrospective Review of 35 Patients".
Moussa A; Kazmi A; Bokhari L; Sinclair RD
J Am Acad Dermatol; 2022 Jul; 87(1):e31-e32. PubMed ID: 35304166
[No Abstract] [Full Text] [Related]
70. Sense and Sensibility.
Schattner A
Am J Med; 2021 Dec; 134(12):1570-1571. PubMed ID: 34214460
[No Abstract] [Full Text] [Related]
71. New indication sought for bicalutamide.
Oncology (Williston Park); 2000 May; 14(5):654, 772. PubMed ID: 10853458
[No Abstract] [Full Text] [Related]
72. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
Petit JH; Gluck C; Kiger WS; Henry DL; Karasiewicz C; Talcott J; Berg S; Holupka E; Kaplan I
Urol Oncol; 2008; 26(4):372-7. PubMed ID: 18367113
[TBL] [Abstract][Full Text] [Related]
73. Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
Molenaar JP; Baten A; Blokx WA; Hoogendam A
Eur Urol; 2009 Nov; 56(5):874-7; quiz 876. PubMed ID: 19171417
[TBL] [Abstract][Full Text] [Related]
74. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.
Locati LD; Perrone F; Cortelazzi B; Lo Vullo S; Bossi P; Dagrada G; Quattrone P; Bergamini C; Potepan P; Civelli E; Fallai C; Pilotti S; Licitra L
Head Neck; 2016 May; 38(5):724-31. PubMed ID: 25522335
[TBL] [Abstract][Full Text] [Related]
75. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
76. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program.
Brawer MK
BJU Int; 2003 Apr; 91(6):465-6. PubMed ID: 12656893
[No Abstract] [Full Text] [Related]
77. Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.
Xu M; Sakamoto S; Matsushima J; Kimura T; Ueda T; Mizokami A; Kanai Y; Ichikawa T
J Urol; 2016 May; 195(5):1588-1597. PubMed ID: 26682754
[TBL] [Abstract][Full Text] [Related]
78. Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome.
Tessaris D; Matarazzo P; Mussa A; Tuli G; Verna F; Fiore L; Lala R
Endocr J; 2012; 59(2):111-7. PubMed ID: 22068112
[TBL] [Abstract][Full Text] [Related]
79. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
Yamamoto N; Minami S; Fujii M
Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
[TBL] [Abstract][Full Text] [Related]
80. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy.
Pirl WF; Greer JA; Goode M; Smith MR
Psychooncology; 2008 Feb; 17(2):148-53. PubMed ID: 17443645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
